For example, a HER2-targeted DNA vaccine trial initiated in 2011 demonstrated long-term efficacy; ten-year follow-up data published in 2023 indicated that most participating women with advanced-stage HER2-positive breast cancer remained cancer-free [289]. This evidence concerns the gene ERBB2 and breast carcinoma.